Kassenärztliche Bundesvereinigung

KBV

Die Aufgaben der KBV: Politische Vertretung auf Bundesebene Die KBV vertritt die Belange der Vertragsärzte bei Gesetzgebungsverfahren und bringt den Sachverstand der niedergelassenen Ärzte und Psychotherapeuten in die gesundheitspolitische Diskussion auf Bundesebene ein. Vertretung (der niedergelassenen Ärzte) gegenüber den Krankenkassen Als genossenschaftlicher Zusammenschluss wahren die KBV beziehungsweise die KVen die Rechte und die wirtschaftlichen Interessen der Vertragsärzte und Psychotherapeuten gegenüber den Krankenkassen (§75 SGB V). Eine Reihe von Verträgen verhandelt die KBV direkt mit den Krankenkassen und anderen Leistungsträgern. Dazu zählen Änderungen im Leistungskatalog der gesetzlichen Krankenversicherung und der Einheitliche Bewertungsmaßstab (EBM). Der EBM ist die bundeseinheitlich geltende Gebührenordnung der niedergelassenen Ärzte und Psychotherapeuten. Sicherstellungsauftrag Im Rahmen des Sicherstellungsauftrags überwachen die KVen d (...)

Lobbying Activity

Meeting with Andreas Glück (Member of the European Parliament)

10 Sept 2024 · Health

Response to Health technology assessment - Joint clinical assessments of medicinal products

2 Apr 2024

The German Association of Statutory Health Insurance Physicians (KBV) comments on the draft implementing regulation - Ares(2024)1703728 as follows: Article 9 (3) and Article 10 (1): The renewed involvement of patient representatives and clinical experts following the consolidation of the assessment scope proposal by the assessors is not expedient, as the definition of the national PICOs by HTA experts from the respective member states has already been completed at this point. Article 12 (2): A deadline of 90 (60) days for the preparation of a dossier by the health technology developer might be too short to meet the needs of the member states as outlined in the various PICOs included in the assessment scope. Article 12 (7) and Article 14 (5): It is welcomed that current data from clinical trials can be submitted and taken into account during the ongoing JCA procedure. However, based on the existing deadlines and the high number of necessary analyses, the practical feasibility of this option is questioned. Article 14 (4) and Article 20: The JCA report and the summary report contain the scientific analysis and presentation of aggregated data from the dossier of the health technology developer which reflect the needs of the member states. The documents mentioned should be published in full for reasons of transparency. Article 18 (5): If the update of a JCA is planned, the Member States should in principle have the opportunity to review whether the initially defined assessment scope (PICO) continues to meet their needs on the basis of the current standard of care.
Read full response

Meeting with Karsten Lucke (Member of the European Parliament)

28 Mar 2023 · Long Covid

Meeting with Andreas Glück (Member of the European Parliament, Shadow rapporteur for opinion)

1 Feb 2023 · EHDS

Meeting with Birgit Sippel (Member of the European Parliament, Rapporteur) and Bundesärztekammer

6 Sept 2022 · Exchange of Views on European Health Data Space & eEvidence

Meeting with Vytenis Andriukaitis (Commissioner) and

21 Oct 2016 · Access to medicines, health workforce, AMR